Over the past decade, immune checkpoint inhibitors have shown success in treating several types of cancer, including melanoma, non-small cell lung cancer, small cell lung cancer, kidney cancer, bladder cancer, head and neck cancers, Hodgkin’s lymphoma and Merkel cell carcinoma. And the list continues to grow.
“Immunotherapy is a modern pillar of cancer therapy,” says Vivek Subbiah, M.D., assistant professor of Investigational...
MD Anderson researchers have discovered that a protein called angiogenin (ANG) serves as a potential biomarker useful for stratifying pancreatic...
Somatic mutations in certain genes may function as a molecular minimal residual disease marker for acute myeloid leukemia (AML), according...
Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
encompass a spectrum of diseases characterized by an overproduction of
immature blood cells, resulting in a lack of healthy, mature blood
cells in patients.
Unfortunately, the majority of patients with these diseases are not cured with currently available therapies, so MD Anderson’s MDS and AML Moon Shot™ team has committed to developing new treatment options...
September is Ovarian Cancer Awareness Month, an annual time to bring attention to the impact of the disease. This year, more than 22,000 women...
Lung cancer immunotherapy triggers a counterattack by a surface protein found on the tumors of some patients that stifles the immune system...
Almost one year after the Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) T-cell therapy for children with...
MD Anderson Cancer Center again has been ranked No. 1 for cancer care by U.S. News & World Report’s annual “Best Hospitals” survey...
A well-trained research workforce is essential for addressing both current and future health challenges in the U.S. However, according to...
MD Anderson Cancer Center and Accelerator Life Science Partners, a leading life science investment and management firm, have launched Magnolia...